Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.28 EUR | -0.48% | +2.73% | +74.32% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 51.07M 54.79M | Sales 2025 * | 58.83M 63.12M | Capitalization | 68.97M 74M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.07M | Net income 2025 * | 3M 3.22M | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | 11.27M 12.09M | Net cash position 2025 * | 12M 12.87M | EV / Sales 2025 * | 0.97 x |
P/E ratio 2024 * |
69
x | P/E ratio 2025 * |
19.1
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 day | -0.48% | ||
1 week | +2.73% | ||
Current month | +30.19% | ||
1 month | +30.19% | ||
3 months | +88.18% | ||
6 months | +142.82% | ||
Current year | +74.32% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
Chairman | 51 | 20-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 8.28 | -0.48% | 3,932 |
24-04-25 | 8.32 | +2.21% | 5,325 |
24-04-24 | 8.14 | +0.99% | 3,304 |
24-04-23 | 8.06 | -0.25% | 1,145 |
24-04-22 | 8.08 | +0.25% | 746 |
Delayed Quote Xetra, April 26, 2024 at 11:36 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+74.32% | 73.63M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- APPH Stock